MX2019001860A - Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab. - Google Patents
Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.Info
- Publication number
- MX2019001860A MX2019001860A MX2019001860A MX2019001860A MX2019001860A MX 2019001860 A MX2019001860 A MX 2019001860A MX 2019001860 A MX2019001860 A MX 2019001860A MX 2019001860 A MX2019001860 A MX 2019001860A MX 2019001860 A MX2019001860 A MX 2019001860A
- Authority
- MX
- Mexico
- Prior art keywords
- ofatumumab
- multiple sclerosis
- treating multiple
- regimens
- methods
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229960002450 ofatumumab Drugs 0.000 title abstract 2
- 229940124292 CD20 monoclonal antibody Drugs 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Abstract
La divulgación está dirigida a regímenes de tratamiento para tratar la esclerosis múltiple (MS). Estos métodos utilizan la administración de ofatumumab, un anticuerpo monoclonal anti-CD20, al paciente durante un régimen de dosis de carga y un régimen de mantenimiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662374986P | 2016-08-15 | 2016-08-15 | |
PCT/IB2017/054909 WO2018033841A1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019001860A true MX2019001860A (es) | 2019-07-08 |
Family
ID=59901554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019001860A MX2019001860A (es) | 2016-08-15 | 2017-08-11 | Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab. |
Country Status (24)
Country | Link |
---|---|
US (3) | US11161909B2 (es) |
EP (3) | EP4252847A3 (es) |
JP (2) | JP6851391B2 (es) |
KR (2) | KR20200136503A (es) |
CN (1) | CN109641965A (es) |
AU (2) | AU2017311664B2 (es) |
CA (2) | CA3030530C (es) |
CY (1) | CY1123350T1 (es) |
DE (1) | DE202017007542U1 (es) |
DK (2) | DK3497132T3 (es) |
ES (2) | ES2954259T3 (es) |
FI (1) | FI3733712T3 (es) |
HR (2) | HRP20230894T1 (es) |
HU (2) | HUE051948T2 (es) |
IL (3) | IL276890B2 (es) |
LT (2) | LT3497132T (es) |
MX (1) | MX2019001860A (es) |
PL (2) | PL3733712T3 (es) |
PT (2) | PT3733712T (es) |
RS (2) | RS60807B1 (es) |
RU (1) | RU2749951C2 (es) |
SI (2) | SI3497132T1 (es) |
TW (1) | TWI752995B (es) |
WO (1) | WO2018033841A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2954259T3 (es) * | 2016-08-15 | 2023-11-21 | Novartis Ag | Regímenes y métodos de tratamiento de la esclerosis múltiple utilizando ofatumumab |
KR20220062027A (ko) | 2019-09-11 | 2022-05-13 | 노파르티스 아게 | 오파투무맙-치료된 환자에서의 다발성 경화증 이외의 병태의 관리 |
LT3864053T (lt) | 2019-09-11 | 2023-09-11 | Novartis Ag | Rms gydymas, pakeičiant terapiją |
KR20230170923A (ko) * | 2021-04-14 | 2023-12-19 | 노파르티스 아게 | 아시아인 환자들에서 ms 치료용 오파투무맙 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
JP2014506258A (ja) * | 2011-01-10 | 2014-03-13 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 新規使用 |
MX363819B (es) | 2012-02-08 | 2019-04-03 | Igm Biosciences Inc | Uniones a cdim y sus usos. |
EP2882741B1 (en) | 2012-08-10 | 2018-10-24 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
CN107407677B (zh) | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
ES2954259T3 (es) * | 2016-08-15 | 2023-11-21 | Novartis Ag | Regímenes y métodos de tratamiento de la esclerosis múltiple utilizando ofatumumab |
-
2017
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active IP Right Cessation
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en active Pending
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en unknown
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Application Discontinuation
- 2017-08-11 MX MX2019001860A patent/MX2019001860A/es unknown
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 AU AU2017311664A patent/AU2017311664B2/en active Active
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 IL IL302488A patent/IL302488A/en unknown
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112B2/en active Active
- 2020-08-31 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US20240150485A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
MX2020004948A (es) | Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación. | |
MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
MX2019001860A (es) | Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab. | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
EA201792209A1 (ru) | Схема введения пропущенных доз инъекционных сложных эфиров палиперидона длительного действия | |
AU2019243283C1 (en) | Methods of treating ulcerative colitis | |
MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
MX2022015115A (es) | Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos. | |
MX2017000366A (es) | Terapia de combinacion para el cancer. | |
BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
MX2018002554A (es) | Combinaciones de inhibidores de btk para tratar mieloma multiple. | |
PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
PH12017500275A1 (en) | Methods of treating depression using nmda modulators | |
MX2017014396A (es) | Tratamiento de mieloma multiple. | |
MX2021010313A (es) | Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38. | |
CO2022009433A2 (es) | Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario | |
MX2021012848A (es) | Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn. | |
MX2021002647A (es) | Metodos de tratamiento de la psoriasis. | |
MX2023007405A (es) | Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. | |
MX2019011847A (es) | Metodo para tratar un efecto secundario de la terapia de celulas t con receptor de antigeno quimerico (car). |